Status:
RECRUITING
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Lead Sponsor:
University Hospital, Alexandroupolis
Conditions:
Renal Function Disorder
Diabetic Macular Edema (DME)
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEG...
Detailed Description
For the purposes of this study, 60 diabetic patients who need intravitreal injections of anti-VEGF for either diabetic macular edema or neovascular age related macular degeneration will be enrolled. 3...
Eligibility Criteria
Inclusion
- Patients with diabetes
- Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
- Patients already receiving nephroprotective drugs
Exclusion
- Patients with end stage renal disease
- Pregnancy
- Patients with other retinal disorders
- Previous renal transplantation Patients under hemodialysis
Key Trial Info
Start Date :
March 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 10 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06929507
Start Date
March 10 2025
End Date
March 10 2027
Last Update
April 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece, 68100
2
University Hospital of Alexandroupolis
Alexandroupoli, Greece, 68100